Instgra Tablet contains Dolutegravir 50 mg, an antiretroviral medication used in the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that works by blocking the HIV integrase enzyme, preventing viral DNA from integrating into the host cell genome, thereby inhibiting viral replication. Instgra is typically prescribed as part of combination antiretroviral therapy (cART) to enhance efficacy and reduce the likelihood of resistance development. It is indicated for use in treatment-naïve and treatment-experienced adult patients with HIV-1 infection. The recommended dosage is one tablet taken orally once daily, with or without food. Instgra has demonstrated a favorable safety profile, with common adverse effects including insomnia, headache, and gastrointestinal disturbances such as nausea and diarrhea. Caution is advised in patients with hepatic impairment and those on concomitant medications that may interact via the UGT1A1 or CYP3A metabolic pathways. Regular monitoring of viral load and CD4 counts is essential to assess therapeutic response. Instgra should be used under medical supervision, with adherence to prescribed regimens to optimize treatment outcomes and minimize resistance development.